Image

Melanoma Research

Featured image for “You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails”
11/07/2025

You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails

Melanoma treatment has advanced dramatically over the past decade, with immunotherapy and targeted therapies offering hope for many patients. However,…
Blog - Melanoma360
Melanoma Research
Featured image for “Immune Checkpoint Inhibition for Melanoma: A Focus on Veterans”
11/02/2025

Immune Checkpoint Inhibition for Melanoma: A Focus on Veterans

Introduction Veterans have been shown to have a higher risk for melanoma compared to the general U.S. population due to…
Blog - Melanoma360
Melanoma Research
Featured image for “Overview of Melanoma in Veterans”
11/02/2025

Overview of Melanoma in Veterans

Considerations Regarding Epidemiology, Risk Factors, Diagnosis, Prognosis, Survival, and Treatment Introduction Distinct health challenges affect veterans both during and after…
Blog - Melanoma360
Melanoma Research
Featured image for “SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma”
10/22/2025

SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma

Rotterdam, The Netherlands – San Diego, CA – [October 22nd] – SkylineDx today announced that results from its landmark MERLIN_001…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “You’re Not Out of Options—What To Do After First Line Therapy Fails”
10/07/2025

You’re Not Out of Options—What To Do After First Line Therapy Fails

Hearing that your treatment for melanoma has stopped working—or that you’ve had to stop because of side effects—can be overwhelming.…
Blog - Melanoma360
Melanoma Research
Featured image for “Newly Published Trial Data for Melanoma”
08/26/2025

Newly Published Trial Data for Melanoma

Focus on TIGIT Immunotherapy What Is Immunotherapy? Many people with healthy immune systems still develop cancer. Sometimes the immune system…
Blog - Melanoma360
Melanoma Research
Featured image for “RP1 + Nivolumab Rejection: Advocating for Patients and Trust in Clinical Trials”
08/26/2025

RP1 + Nivolumab Rejection: Advocating for Patients and Trust in Clinical Trials

FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a…
Blog - Melanoma360
Melanoma Research
Featured image for “IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma”
08/11/2025

IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Understanding Tumor Genetics and Melanoma: A Recap of Our Latest Webinar”
07/18/2025

Understanding Tumor Genetics and Melanoma: A Recap of Our Latest Webinar

In the age of precision medicine, understanding the genetics of a tumor—not just a person’s inherited DNA—is playing a critical…
Blog - Melanoma360
Melanoma Research
Featured image for “Melanoma News and Highlights You Don’t Want to Miss”
06/18/2025

Melanoma News and Highlights You Don’t Want to Miss

We know staying informed about melanoma research and treatments is important to you. That’s why we’ve put together some of…
Blog - Melanoma360
Melanoma Research
11/07/2025

You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails

Melanoma treatment has advanced dramatically over the past decade, with immunotherapy and targeted therapies offering hope for many patients. However,…
Featured image for “You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails”
Blog - Melanoma360
 | 
Melanoma Research
11/02/2025

Immune Checkpoint Inhibition for Melanoma: A Focus on Veterans

Introduction Veterans have been shown to have a higher risk for melanoma compared to the general U.S. population due to…
Featured image for “Immune Checkpoint Inhibition for Melanoma: A Focus on Veterans”
Blog - Melanoma360
 | 
Melanoma Research
11/02/2025

Overview of Melanoma in Veterans

Considerations Regarding Epidemiology, Risk Factors, Diagnosis, Prognosis, Survival, and Treatment Introduction Distinct health challenges affect veterans both during and after…
Featured image for “Overview of Melanoma in Veterans”
Blog - Melanoma360
 | 
Melanoma Research
10/22/2025

SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma

Rotterdam, The Netherlands – San Diego, CA – [October 22nd] – SkylineDx today announced that results from its landmark MERLIN_001…
Featured image for “SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/07/2025

You’re Not Out of Options—What To Do After First Line Therapy Fails

Hearing that your treatment for melanoma has stopped working—or that you’ve had to stop because of side effects—can be overwhelming.…
Featured image for “You’re Not Out of Options—What To Do After First Line Therapy Fails”
Blog - Melanoma360
 | 
Melanoma Research
08/26/2025

Newly Published Trial Data for Melanoma

Focus on TIGIT Immunotherapy What Is Immunotherapy? Many people with healthy immune systems still develop cancer. Sometimes the immune system…
Featured image for “Newly Published Trial Data for Melanoma”
Blog - Melanoma360
 | 
Melanoma Research
08/26/2025

RP1 + Nivolumab Rejection: Advocating for Patients and Trust in Clinical Trials

FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a…
Featured image for “RP1 + Nivolumab Rejection: Advocating for Patients and Trust in Clinical Trials”
Blog - Melanoma360
 | 
Melanoma Research
08/11/2025

IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase…
Featured image for “IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
07/18/2025

Understanding Tumor Genetics and Melanoma: A Recap of Our Latest Webinar

In the age of precision medicine, understanding the genetics of a tumor—not just a person’s inherited DNA—is playing a critical…
Featured image for “Understanding Tumor Genetics and Melanoma: A Recap of Our Latest Webinar”
Blog - Melanoma360
 | 
Melanoma Research
06/18/2025

Melanoma News and Highlights You Don’t Want to Miss

We know staying informed about melanoma research and treatments is important to you. That’s why we’ve put together some of…
Featured image for “Melanoma News and Highlights You Don’t Want to Miss”
Blog - Melanoma360
 | 
Melanoma Research